Surotomycin

DRUG3 trials

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Merck Sharp & Dohme LLC

Conditions

Clostridium Difficile Associated Diarrhea (CDAD)Clostridium Difficile Infection

Phase 1

A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)

CompletedNCT02835118

Merck Sharp & Dohme LLCClostridium Difficile Associated Diarrhea (CDAD)

Start: 2009-07-31End: 2009-10-31Updated: 2016-07-22

A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)

CompletedNCT02835105

Merck Sharp & Dohme LLCClostridium Difficile Associated Diarrhea (CDAD)

Start: 2009-01-31End: 2009-03-31Updated: 2016-07-22

Phase 3

Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)

CompletedNCT01597505

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Clostridium Difficile Infection

Start: 2012-05-16End: 2015-03-20Updated: 2019-07-23

Related Papers

Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities

Journal of Antimicrobial Chemotherapy2020-07-307 citations

Pharmacokinetics of surotomycin from phase 1 single and multiple ascending dose studies in healthy volunteers.

2017-03-289 citations